Jefferies Highlights Revolution Medicines, Inc. (RVMD)'s RAS(ON) Platform in Coverage Initiation [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Revolution Medicines, Inc. is one of the best Robinhood stocks. TheFly reported on March 16 that Jefferies initiated coverage of RVMD with a Buy rating and set a price target of $140, up from $88. The firm emphasized the potential of its RAS(ON) platform and positioned itself as a key innovation in oncology. According to Jefferies, the Phase 3 RASolute 302 trial is expected to accomplish its first interim endpoints, indicating a favorable path for the company's clinical and commercial outlook. Daraxonrasib is recognized as having great possibilities to transform treatment for second-line pancreatic cancer. Separately, Revolution Medicines, Inc. (NASDAQ:RVMD) declared on March 17 that it will provide important updates from its pipeline of RAS(ON) inhibitors at the 2026 American Association for Cancer Research (AACR) Annual Meeting, which is set for April 17–22 in San Diego. Jefferies Highlights Revolution Medicines, Inc. (RVMD)'s RAS(ON) Platform in Coverage Initiation New Phas
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire
- A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now? [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/26/26 - Form 4
- 3/26/26 - Form 144
- RVMD's page on the SEC website